株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

EpiCast Report:加齢黄斑変性症の疫学予測

EpiCast Report: Age-Related Macular Degeneration - Epidemiology Forecast to 2026

発行 GlobalData 商品コード 312373
出版日 ページ情報 英文 38 Pages
即納可能
価格
本日の銀行送金レート: 1USD=114.58円で換算しております。
Back to Top
EpiCast Report:加齢黄斑変性症の疫学予測 EpiCast Report: Age-Related Macular Degeneration - Epidemiology Forecast to 2026
出版日: 2017年11月01日 ページ情報: 英文 38 Pages
概要

加齢黄斑変性症(AMD)は、網膜で中心視野を担う、黄斑の段階的な劣化によって引き起こされる、進行性の眼疾患です。世界の主要7ヶ国(米国、フランス、ドイツ、イタリア、スペイン、英国、日本)における加齢黄斑変性症(AMD)の有病件数は、2013年の55,770,401件から、今後10年間で66,069,370件まで、18.5%増加すると予測されています。

当レポートでは、世界の主要7ヶ国における加齢黄斑変性症(AMD)について調査分析し、疾患の背景、危険因子と併存疾患、世界の動向、疫学予測などについて、体系的な情報を提供しています。

第1章 目次

第2章 イントロダクション

第3章 疫学

  • 疾患の背景
  • 危険因子と併存疾患
  • 世界の動向
    • 米国
    • 主要5ヶ国
    • 日本
  • 予測手法
    • 利用した情報源
    • 予測の前提条件と手法
  • AMDの疫学予測
    • AMDの総有病件数
    • AMDの総有病件数:年齢別
    • AMDの総有病件数:性別
    • AMDの総有病率:年齢標準化
    • AMDの総有病件数:段階別
    • AMD後期の総有病件数:サブタイプ別
  • 議論
    • 疫学予測に関する考察
    • 分析の限界
    • 分析の強み

第4章 付録

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GDHCER170-17

Age-related macular degeneration (AMD) is a progressive eye condition that is characterized by the gradual deterioration of the macula, which is the area of the retina responsible for central vision. AMD is the most common cause of significant irreversible vision loss among the elderly (NEI, 2015; NHS, 2015). AMD is classified into three stages: early AMD, intermediate AMD, and late AMD. Early AMD is characterized by the presence of drusen (tiny yellow or white accumulations of extracellular material at the back of the eye) and/or focal pigmentary changes, both of which precede significant visual loss.

The total prevalent cases of AMD in the 7MM will increase from in the 7MM will increase from around 71 million cases in 2016 to almost 83 millioncases in 2026, at an Annual Growth Rate(AGR) of about 1.6% over the forecast period. Throughout the forecast period,Japan will have the highest number of total prevalent cases of AMD, followed by Italy.The total prevalent cases of AMD in Japan and Italy combined will make upapproximately39% of the total prevalent cases of AMD in the 7MM. GlobalData epidemiologists attribute the growth in the total prevalent cases of AMD in the 7MM to the changing population demographics in the respective markets.

The diagnosed incident cases of AMD in the 7MM will increase from around 11.2 million cases in 2016 to nearly 13 million cases in 2026, at an AGR of almost 1.5%. Throughout the forecast period,Japan will have the highest number of diagnosed incident cases of AMD, followed by Italy.The diagnosed incident cases of AMD in Japan and Italy combined will make up approximately40% of the diagnosed incident cases of AMD in the 7MM. GlobalData epidemiologists attribute the growth in the diagnosed incident cases of AMD in the 7MM to the changing population demographics in the respective markets.

The report "EpiCast Report: Age-Related Macular Degeneration - Epidemiology Forecast to 2026", provides an overview of the risk factors, comorbidities, and the global and historical trends for AMD in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan).The reportalso includes a 10-year epidemiological forecast for the total prevalent cases of AMD, early AMD, late AMD, late dry AMD, and late wet AMD, all of which are segmented by sex and age (ages 50 years and older) in these markets.

Scope

  • The Age-related Macular Degeneration (AMD) EpiCast Report provides an overview of the risk factors and global trends of AMD in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan).
  • The report also includes a 10-year epidemiological forecast for the total prevalent cases of AMD, early AMD, late AMD, late dry AMD, and late wet AMD, all of which are segmented by sex and age (ages 50 years and older) in these markets. GlobalData epidemiologists also provided the diagnosed incident cases of AMD, early AMD, late AMD, late dry AMD, and late wet AMD, all of which are segmented by sex and age (ages 50 years and older). Additionally, the report includes a 10-year epidemiological forecast for the total prevalent cases and diagnosed incident cases of large drusen (≥125 µm) segmented by sex and age (ages 50 years and older) in these markets.
  • The AMD epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
  • The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.

Reasons to buy

The AMD EpiCast report will allow you to -

  • Develop business strategies by understanding the trends shaping and driving the global AMD market.
  • Quantify patient populations in the global AMD market to improve product design, pricing, and launch plans.
  • Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for AMD therapeutics in each of the markets covered.
  • Understand magnitude of AMD population by type.

Table of Contents

1 Table of Contents

1 Table of Contents 2

  • 1.1 List of Tables 4
  • 1.2 List of Figures 4

2 Age-Related Macular Degeneration: Executive Summary 5

  • 2.1 Related Reports 7
  • 2.2 Upcoming Reports 7

3 Epidemiology 8

  • 3.1 Disease Background 8
  • 3.2 Risk Factors and Comorbidities 8
  • 3.3 Global and Historical Trends 9
  • 3.4 Forecast Methodology 10
    • 3.4.1 Sources 12
    • 3.4.2 Forecast Assumptions and Methods 13
    • 3.4.3 Total Prevalent Cases of AMD, Early AMD, Late AMD, Late Dry AMD, Late Wet AMD, and Large Drusen 14
    • 3.4.4 Diagnosed Incident Cases of AMD, Early AMD, Late AMD, Late Dry AMD, Late Wet AMD, and Large Drusen 18
  • 3.5 Epidemiological Forecast for AMD (2016-2026) 20
    • 3.5.1 Total Prevalent Cases of AMD 20
    • 3.5.2 Age-Specific Total Prevalent Cases of AMD 20
    • 3.5.3 Sex-Specific Total Prevalent Cases of AMD 22
    • 3.5.4 Total Prevalent Cases of Early AMD 22
    • 3.5.5 Total Prevalent Cases of Late AMD 23
    • 3.5.6 Total Prevalent Cases of Late Dry AMD 24
    • 3.5.7 Total Prevalent Cases of Late Wet AMD 24
    • 3.5.8 Total Prevalent Cases of Large Drusen 25
    • 3.5.9 Diagnosed Incident Cases of AMD 26
    • 3.5.10 Age-Specific Diagnosed Incident Cases of AMD 27
    • 3.5.11 Sex-Specific Diagnosed Incident Cases of AMD 27
    • 3.5.12 Diagnosed Incident Cases of Early AMD 28
    • 3.5.13 Diagnosed Incident Cases of Late AMD 29
    • 3.5.14 Diagnosed Incident Cases of Late Dry AMD 30
    • 3.5.15 Diagnosed Incident Cases of Late Wet AMD 30
    • 3.5.16 Diagnosed Incident Cases of Large Drusen 31
  • 3.6 Discussion 32
    • 3.6.1 Epidemiological Forecast Insight 32
    • 3.6.2 Limitations of the Analysis 32
    • 3.6.3 Strengths of the Analysis 33

4 Appendix 34

  • 4.1 Bibliography 34
  • 4.2 About the Authors 36
    • 4.2.1 Epidemiologist 36
    • 4.2.2 Reviewers 36
    • 4.2.3 Global Director of Therapy Analysis and Epidemiology 37
    • 4.2.4 Global Head and EVP of Healthcare Operations and Strategy 37
  • 4.3 About GlobalData 38
  • 4.4 Contact Us 38
  • 4.5 Disclaimer 38

List of Tables

1.1 List of Tables

  • Table 1: Risk Factors and Comorbid Conditions Associated with AMD 9
  • Table 2: Classification of AMD 11
  • Table 3: 7MM, Total Prevalent Cases of AMD, Both Sexes, Ages ≥50 Years, N, Selected Years 2016-2026 20
  • Table 4: 7MM, Total Prevalent Cases of Early AMD, Both Sexes, Ages ≥50 Years, N, Selected Years 2016-2026 23
  • Table 5: 7MM, Total Prevalent Cases of Late AMD, Both Sexes, Ages ≥50 Years, N, Selected Years 2016-2026 23
  • Table 6: 7MM, Total Prevalent Cases of Late Dry AMD, Both Sexes, Ages ≥50 Years, N, Selected Years 2016-2026 24
  • Table 7: 7MM, Total Prevalent Cases of Late Wet AMD, Both Sexes, N, Ages ≥50 Years, Selected Years 2016-2026 25
  • Table 8: 7MM, Total Prevalent Cases of Large Drusen, Both Sexes, Ages ≥50 Years, N, Selected Years 2016-2026 25
  • Table 9: 7MM, Diagnosed Incident Cases of AMD, Both Sexes, Ages ≥50 Years, N, Selected Years 2016-2026 26
  • Table 10: 7MM, Diagnosed Incident Cases of Early AMD, Both Sexes, Ages ≥50 Years, N, Selected Years 2016-2026 29
  • Table 11: 7MM, Diagnosed Incident Cases of Late AMD, Both Sexes, Ages ≥50 Years, N, Selected Years 2016-2026 29
  • Table 12: 7MM, Diagnosed Incident Cases of Late Dry AMD, Both Sexes, Ages ≥50 Years, N, Selected Years 2016-2026 30
  • Table 13: 7MM, Diagnosed Incident Cases of Late Wet AMD, Both Sexes, Ages ≥50 Years, N, Selected Years 2016-2026 31
  • Table 14: 7MM, Diagnosed Incident Cases of Large Drusen, Both Sexes, Ages ≥50 Years, N, Selected Years 2016-2026 31

List of Figures

1.2 List of Figures

  • Figure 1: 7MM, Total Prevalent Cases of AMD, Both Sexes, Ages ≥50 Years, N, 2016 and 2026 6
  • Figure 2: 7MM, Diagnosed Incident Cases of AMD, Both Sexes, Ages ≥50 Years, N, 2016 and 2026 7
  • Figure 3: 7MM, Age-Standardized Total Prevalence of AMD (%), Men and Women, Ages ≥50 Years, 2016 10
  • Figure 4: 7MM, Sources Used, Total Prevalent Cases of AMD, Early AMD, Late AMD, Late Dry AMD, Late Wet AMD, and Large Drusen 12
  • Figure 5: 7MM, Sources Used, Diagnosed Incident Cases of AMD, Early AMD, Late AMD, Late Dry AMD, Late Wet AMD, and Large Drusen 13
  • Figure 6: 7MM, Age-Specific Total Prevalent Cases of AMD, Both Sexes, N, 2016 21
  • Figure 7: 7MM, Sex-Specific Total Prevalent Cases of AMD, Ages ≥50 Years, N, 2016 22
  • Figure 8: 7MM, Age-Specific Diagnosed Incident Cases of AMD, Both Sexes, N, 2016 27
  • Figure 9: 7MM, Sex-Specific Diagnosed Incident Cases of AMD, Ages ≥50 Years, N, 2016 28
Back to Top